Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

The global brain biomarkers market is poised for remarkable growth, fueled by the escalating prevalence of neurological disorders and rapid technological advancements. A recent market analysis reveals ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

The massive pharmacy benefit manager plans to stop requiring coverage reauthorizations for roughly 80 drugs used to treat migraines, multiple sclerosis, high cholesterol and more.

The company has delivered on its $4 billion net cost savings target from the ongoing cost realignment program and has increased its overall savings target to ~$4.5 billion by the end of the year.